Clinical trials: LUTS
Benign Prostatic Hyperplasia
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- NCT01454349
- Testing
- PRX302
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia
Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH
The high level of unsatisfactory outcome observed in patients treated for LUTS associated with BPH with respect to the different existing therapeutic options strongly emphasizes the need for treatment optimisation in daily…
- Trial name
- UROEVAL (NCT03179670)
- Where
- France
- Volunteers
- 625 people
- Sponsor
- RECORDATI GROUP
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device.
- Trial name
- Omega (NCT05757687)
- Testing
- Omega device
- Where
- 5 sites in Georgia
- Volunteers
- 11 people
- Sponsor
- ProArc Medical
BPH, Lower Urinary Tract Symptoms
Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS)
This study will evaluate LycoComfort™ supplementation in alleviating symptoms associated with LUTS, BPH, and general prostate concerns.
- Trial name
- NCT03772808
- Testing
- Lycocomfort
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- LycoRed Ltd.
Benign Prostatic Hypertrophy
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy…
- Trial name
- NCT00427219
- Testing
- Ozarelix
- Where
- 13 sites in United States
- Volunteers
- 74 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Prostate Cancer
Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues
The intention of this study is to investigate how many patients with prostate cancer, planned to be treated with LHRH analogues without history of surgery or radiotherapy, are suffering from LUTS.
- Trial name
- ANALUTS (NCT02542501)
- Where
- 32 sites in Portugal, Spain
- Volunteers
- 470 people
- Sponsor
- Ipsen
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Lower Urinary Tract Predominant Storage Symptoms
Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)
This study is a non interventional study where no investigational medicine is provided. Procedures and examination will follow the institution standard of care practice.
- Trial name
- VENICE (NCT01799902)
- Testing
- Solifenacin
- Where
- 15 sites in Belgium
- Volunteers
- 86 people
- Sponsor
- Astellas Pharma Europe B.V.
Lower Urinary Tract Symptoms (LUTS)
Effects of Macanity on Urinary Health in Males With Lower Urinary Tract Symptoms
The goal of this study is to evaluate the effects of Macanity on urinary health in males experiencing LUTS. Males aged over 40 years of age who experience LUTS will be recruited and assigned to a study treatment which they will…
- Trial name
- NCT07816172
- Testing
- Maca Root
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Benign Prostatic Hyperplasia
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the…
- Trial name
- RAPID-III (NCT06849258)
- Testing
- FloStent
- Where
- 20 sites in United States, Australia
- Volunteers
- 215 people
- Sponsor
- Rivermark Medical
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS…
- Trial name
- Neptune (NCT01018511)
- Testing
- tamsulosin hydrochloride OCAS 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- Where
- 118 sites in Austria, Belarus and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Astellas Pharma Europe B.V.
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
A study to evaluate the safety of the co-administration of solifenacin succinate with tamsulosin hydrochloride in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO).
- Trial name
- NCT00507455
- Testing
- solifenacin succinate, tamsulosin hydrochloride
- Where
- 33 sites in United States, Belgium and 4 more
- Volunteers
- 222 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia
Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS
Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic
- Trial name
- GL2702 (NCT02303769)
- Testing
- Tamsulosin HCL 0.4mg, Tamsulosin HCL 0.2mg
- Where
- South Korea
- Volunteers
- 309 people
- Sponsor
- GL Pharm Tech Corporation
Benign Prostatic Hyperplasia (BPH)
French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Single arm, multi-center prospective clinical trial to determine the safety and effectiveness of the AQUABEAM System in the treatment of benign prostatic hyperplasia (BPH) in men 45 to 80 years of age.
- Trial name
- NCT03191734
- Testing
- AQUABEAM System
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- PROCEPT BioRobotics
Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
This non-randomized, interventional study will be conducted in a general practice setting to assess the utility of a benign prostatic enlargement (BPE)/benign prostatic obstruction (BPO) screening tool in conjunction with…
- Trial name
- NCT02757963
- Testing
- Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool
- Where
- 45 sites in France, Germany and 3 more
- Volunteers
- 1,679 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Optilume™ BPH Catheter System in Men With Symptomatic BPH
PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)
- Trial name
- PINNACLE (NCT04131907)
- Testing
- Optilume BPH Catheter System
- Where
- 21 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Urotronic Inc.
Benign Prostatic Hyperplasia, Localized Prostate Cancer
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are…
- Trial name
- NCT06051942
- Testing
- Robotic Waterjet Treatment
- Where
- 6 sites in United States, Hong Kong and 2 more
- Volunteers
- 125 people
- Sponsor
- PROCEPT BioRobotics
BPH (Benign Prostatic Hyperplasia)
RT-310 Safety and Feasibility BPH Study
RT-310, is intended to deliver drug locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects.
- Trial name
- NCT07264205
- Testing
- RT-310
- Where
- Dominican Republic
- Volunteers
- 20 people
- Sponsor
- Resurge Therapeutics Inc.
Non-muscle Invasive Bladder Cancer (NMIBC)
Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.
This will be an open-label, prospective, single-centre, randomised, controlled, parallel-group medical device investigation. The investigational plan will include four visits in total at the investigational site.
- Trial name
- NCT06069453
- Testing
- Hyaluronic Acid (HA) sodium salt and Hydeal-D
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB)
Vesitirim™ in Men Postmarketing Observational Study
This is an observational study which will look at the improvement in Lower Urinary Tract Symptoms (LUTS) in Irish men being treated with Vesitirim™ (solifenacin).
- Trial name
- VIM (NCT01639794)
- Testing
- Vesitirim™ (Solifenacin)
- Where
- 5 sites in Ireland
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe Ltd.